PMID- 26534742
OWN - NLM
STAT- MEDLINE
DCOM- 20160819
LR  - 20161020
IS  - 1539-6304 (Electronic)
IS  - 1088-5412 (Linking)
VI  - 36
IP  - 6
DP  - 2015 Nov-Dec
TI  - Serum eosinophil-derived neurotoxin: correlation with persistent airflow 
      limitation in adults with house-dust mite allergic asthma.
PG  - e113-20
LID - 10.2500/aap.2015.36.3884 [doi]
AB  - BACKGROUND: The serum level of eosinophil-derived neurotoxin (EDN), a protein 
      present in eosinophil granules, correlates with the severity of childhood asthma. 
      However, the relationship between the serum EDN level and the severity of adult 
      asthma has not been sufficiently investigated. OBJECTIVE: This study aimed to 
      elucidate the correlation between the serum EDN level and markers of severity in 
      adult asthma. METHODS: The subjects comprised 83 adult patients who had asthma 
      and who were undergoing treatment. Of these patients, 40 were positive for 
      house-dust-specific immunoglobulin E (IgE) antibodies; 9 patients with severe 
      adult asthma who were treated with omalizumab were included in the study. We 
      measured the blood eosinophil count, serum EDN, and eosinophil cationic protein 
      levels before investigating the correlations of these parameters with lung 
      function and symptom score. RESULTS: There were no significant correlations 
      between the blood eosinophil count or serum EDN or eosinophil cationic protein 
      level with lung function and the symptom score in patients with asthma. However, 
      serum EDN level was inversely correlated with the decrease percentage forced 
      expiratory volume in 1 second (%FEV1) in patients positive for 
      house-dust-specific IgE antibody (R = -0.54; p < 0.05), whereas no such 
      correlation was observed in patients with negative results for 
      house-dust-specific IgE antibody (R = 0.11; p = 0.468). A significant correlation 
      was observed between a decrease in serum EDN level from baseline and lung 
      function improvement after 8 weeks of omalizumab therapy (R = -0.77; p = 0.015). 
      CONCLUSION: Serum EDN level may be a useful marker for monitoring persistent 
      airflow limitation in adult patients with asthma who had positive results for 
      house-dust-specific IgE antibodies.
FAU - Gon, Yasuhiro
AU  - Gon Y
AD  - Division of Respiratory Medicine, Department of Internal Medicine, Nihon 
      University School of Medicine, Tokyo, Japan.
FAU - Ito, Reiko
AU  - Ito R
FAU - Hattori, Tomohiro
AU  - Hattori T
FAU - Hiranuma, Hisato
AU  - Hiranuma H
FAU - Kumasawa, Fumio
AU  - Kumasawa F
FAU - Kozu, Yutaka
AU  - Kozu Y
FAU - Endo, Daisuke
AU  - Endo D
FAU - Koyama, Daisuke
AU  - Koyama D
FAU - Shintani, Yoshitaka
AU  - Shintani Y
FAU - Eriko, Tsuboi
AU  - Eriko T
FAU - Soda, Kaori
AU  - Soda K
FAU - Maruoka, Shuichiro
AU  - Maruoka S
FAU - Hashimoto, Shu
AU  - Hashimoto S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Allergy Asthma Proc
JT  - Allergy and asthma proceedings
JID - 9603640
RN  - 0 (Anti-Asthmatic Agents)
RN  - 0 (Biomarkers)
RN  - 2P471X1Z11 (Omalizumab)
RN  - EC 3.1.- (Eosinophil-Derived Neurotoxin)
RN  - EC 3.1.27.- (Eosinophil Cationic Protein)
SB  - IM
MH  - Animals
MH  - Anti-Asthmatic Agents/therapeutic use
MH  - Asthma/*blood/diagnosis/etiology/physiopathology/therapy
MH  - Biomarkers
MH  - Cross-Sectional Studies
MH  - Eosinophil Cationic Protein/blood
MH  - Eosinophil-Derived Neurotoxin/*blood
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Omalizumab/therapeutic use
MH  - Pyroglyphidae/immunology
MH  - Respiratory Function Tests
MH  - Risk Factors
MH  - Severity of Illness Index
MH  - Treatment Outcome
EDAT- 2015/11/05 06:00
MHDA- 2016/08/20 06:00
CRDT- 2015/11/05 06:00
PHST- 2015/11/05 06:00 [entrez]
PHST- 2015/11/05 06:00 [pubmed]
PHST- 2016/08/20 06:00 [medline]
AID - 10.2500/aap.2015.36.3884 [doi]
PST - ppublish
SO  - Allergy Asthma Proc. 2015 Nov-Dec;36(6):e113-20. doi: 10.2500/aap.2015.36.3884.